Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 13;12(6):ofaf312.
doi: 10.1093/ofid/ofaf312. eCollection 2025 Jun.

Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023

Ahmed D Elnaiem  1   2 , Anand B Chukka  1 , Cynthia M So-Armah  3   4 , MaryCatherine E Arbour  1   5   6 , Chuan-Chin Huang  1   5 , Daniel A Solomon  1   7 , Lauren E Malishchak  1   3 , Chase G Yarbrough  1   5
Affiliations

Racial and Sociodemographic Disparities in Hepatitis C Treatment at an Urban Academic Medical Center, 2018-2023

Ahmed D Elnaiem et al. Open Forum Infect Dis. .

Abstract

Background: Hepatitis C virus (HCV) disproportionately affects racial minorities and socially disadvantaged groups in the United States. Despite highly effective direct-acting antiviral (DAA) therapies, treatment disparities persist.

Methods: We conducted a retrospective cohort study using electronic medical record data from both inpatient and outpatient settings in an urban academic medical center between 1 October 2018 and 1 October 2023. Multivariable logistic regression identified sociodemographic and clinical predictors of HCV treatment initiation, defined as a documented direct-acting antiviral prescription, among individuals with positive HCV RNA between 2018 and 2023.

Results: Among 4345 individuals, 1150 (26.5%) were prescribed HCV treatment. Black individuals were less likely to be prescribed HCV treatment compared to White individuals (adjusted odds ratio [aOR], 0.68 [95% confidence interval {CI}, .53-.88]). Individuals experiencing homelessness (aOR, 0.57 [95% CI, .46-.69]) and those with Medicaid (aOR, 0.82 [95% CI, .68-.98]) or no insurance (aOR, 0.49 [95% CI, .37-.65]) were also less likely to be prescribed HCV treatment. Individuals with mental health diagnoses (aOR, 1.34 [95% CI, 1.11-1.61]) were more likely to receive HCV treatment. Untreated individuals had a higher percentage of inpatient (12.3%) and emergency department visits (17.7%) than those who received treatment (3.4% and 4.8%, respectively).

Conclusions: Significant disparities in HCV treatment initiation were observed, with lower rates among Black individuals, those experiencing homelessness, and individuals with Medicaid or no insurance. These inequities perpetuate a disproportionate burden of liver disease and preventable mortality in already marginalized populations.

Keywords: direct-acting antivirals; healthcare disparities; hepatitis C; treatment access; urban healthcare.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. All authors: No reported conflicts of interest.

Figures

Graphical Abstract
Graphical Abstract
This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/persistent-disparities-in-hcv-treatment-despite-progressive-policies-retrospective-cohort-study-at-mass-general-brigham-2018-2023?utm_campaign=tidbitlinkshare&utm_source=ITP
See this image and copyright information in PMC

References

    1. Abbasi J. Former NIH director Francis S. Collins on the new White House Plan to Eliminate Hepatitis C. JAMA 2023; 329:1246–7. - PubMed
    1. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C virus and hepatocellular carcinoma: a narrative review. J Clin Transl Hepatol 2018; 6:79–84. - PMC - PubMed
    1. Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin 2015; 44:717–34. - PMC - PubMed
    1. World Health Organization (WHO) . Hepatitis and STIs programmes (HHS), health product policy and standards (HPS). Global hepatitis report 2024: action for access in low- and middle-income countries. 1st ed. Geneva, Switzerland: WHO, 2024:viii–ix.
    1. Bryce K, Smith C, Burns F, Rodger A, Macdonald D. Understanding barriers and enablers to hepatitis C treatment initiation: a systematic review of qualitative studies. Gut 2024; 73:A98–9.